M-PREG

Project at a glance

Executive summary

Preeclampsia is a life-threatening pregnancy complication affecting millions globally. While MirZyme Therapeutics identified the biological markers to predict it, they needed a technology partner to translate that science into a usable clinical tool.

Imobisoft provided the custom medical software development needed to create M-PREG: the world’s first and only UKCA-marked digital diagnostic platform that accurately identifies women at risk of developing preeclampsia. By engineering a secure, cloud-based architecture, we enabled clinicians to detect risk with 93% accuracy without expensive hardware.

The challenge: A public health crisis

Preeclampsia is a common condition in pregnancy, which can be life-threatening for both mother and baby in severe cases. 

It is often difficult to diagnose, and hence the term “silent killer”. The symptoms may include high blood pressure and multiple organ damage in the mother, leading to premature delivery of the baby.

• Impact: Affects nearly 10% of pregnancies. In the UK alone, 40,000 pregnant women are diagnosed with preeclampsia, costing the NHS over £300 million per year.
• The gap: Existing treatments like low-dose aspirin are largely ineffective, offering only a 2-5% risk reduction. Meanwhile, the biological markers (Hmox1 and VEGF) were known to MirZyme’s scientists, but there was no scalable way to deliver this analysis to clinics worldwide.
• The human cost: Preeclampsia claims a life every minute, totalling over 1,500 deaths daily. It also severely impacts fetal development, causing up to one in four cases of fetal growth restriction (FGR) and one in five of all pre-term births.
• Technical barrier: The solution required handling sensitive patient data with extreme security to meet medical device regulations (UKCA) while remaining accessible on standard devices.

The solution: M-PREG digital platform

Imobisoft acted as the technical engine behind MirZyme’s scientific breakthrough. We developed a Software as a Medical Device (SaMD) solution that prioritised accessibility and compliance.

1. Cloud-based diagnostic architecture

We engineered a secure, scalable backend that ingests blood test data and processes it using MirZyme’s proprietary algorithms. This eliminated the need for physical testing kits, allowing the software to run on existing clinical computers and tablets.

2. Algorithm integration & accuracy

Our development team translated complex biological logic into high-performance code. The system analyses defects in the Hmox1 and VEGF pathways instantly, delivering a “Rule-In” diagnosis with 93% accuracy, significantly higher than standard methods.

3. UX for clinical environments

Recognising that doctors are time-poor, we designed a user interface (UI) that requires minimal training. Clinicians can input data and receive a risk profile in seconds.

The results: Impact & ROI

The partnership between Imobisoft and MirZyme successfully bridged the gap between biotech and healthtech.

• Regulatory success: The platform achieved UKCA certification, a rigorous standard for medical devices in the UK.
• Cost reduction: Zero hardware costs for hospitals, projected to save healthcare systems billions by preventing premature births.
• Scalability: The digital-first infrastructure allows M-PREG to be deployed instantly to any clinic with internet access.

FAQs

Who developed the M-PREG diagnostic platform? 

M-PREG was developed through a partnership between MirZyme Therapeutics (Scientific Research) and Imobisoft  (Software Development & Engineering).

How does the M-PREG digital test work? 

M-PREG works as a cloud-based application. Clinicians upload standard blood test results to the secure platform, which uses an algorithm to analyse biomarkers and return an instant risk assessment.

Is the M-PREG platform secure? 

Yes. Imobisoft built the M-PREG platform with enterprise-grade security protocols to ensure full compliance with medical data privacy laws and UKCA regulations.

“M-PREG transforms maternal care by enabling timely intervention… delivered through a clinically practical test built on robust digital infrastructure.”

Looking for a partner to build your medical software? 

Imobisoft specialises in turning complex medical science into certified digital products.